Woman surviving cancer thanks to experimental drug from Manchester hospital

A woman with deadly bile duct cancer is surviving against all the odds thanks to a new experimental drug.

Carol Hardy, from Penrith, Cumbria, is taking part in a clinical trial the Christie NHS Foundation Trust in Manchester, and doctors hope the drug may eventually be used for a range of cancers.

The tablets – known only as RXC004 – contain a compound that blocks a pathway known to be over-activated in bile duct cancer.

So far, the treatment is working and has shrunk the 65-year-old's tumour to just over a fifth of its original size.

Mrs Hardy said:  "I just can't believe it. I mean if I hadn't gone to Christie's I just wouldn't be alive. 

“The trial is what's kept me alive and Christies is what's kept me alive.

"If I could save one life I would be delighted as well as prolong my own but if this ever came as a cure or any future trial should I have to go on another trial I would do it because you're helping other people as well as helping yourself." 

• Video report by Tim Backsall.

Bile duct cancer is rare, with around 1,000 new cases every year in the UK.

It does not usually cause symptoms in the early stages but can lead to jaundice, itchy skin, weight loss and pain as it progresses.

Most people with bile duct cancer already have advanced cancer by the time they are diagnosed, with the disease having spread to other parts of the body.

Treatment is usually chemotherapy but only around 5% of people live for five years or more after diagnosis.

Mrs Hardy discovered she had bile duct cancer by chance about four years ago after suffering gallstones.

She had also been losing weight without trying.

She said she had a “sinking feeling” when first diagnosed and was worried about what it meant for her husband Simon, now 55, and daughter Holly, now 22.

“My words were: ‘I can’t have cancer, I can’t die because my daughter is only 18.'”

During a long operation, Mrs Hardy’s gallbladder was removed and she was given the all-clear from cancer.

But the following year, a scan showed cancer on her liver and in some lymph nodes, confirming that the disease had spread.

Mrs Hardy was referred to the Christie in Manchester and started a trial of immunotherapy combined with chemotherapy.

This shrank her liver tumour down from 2.4cm in September 2020, to 0.9cm in December 2020 and even further to 0.3cm in November 2021.

However, medics found another small tumour on her liver a few months later.

Mrs Hardy was then put on the trial testing RXC004 and has been on the drug since February.

In the most recent scans, Mrs Hardy’s liver tumour has shrunk from 3.3cm in February to 0.7cm now.

Mrs Hardy said: "I've realised that people weren't aware of Christies, It's purely a cancer hospital and trials to me are the way forward. 

“People who are being cured from cancer now are purely because people have gone on a trial and done as I've done.

"Tablets are much preferable to the six hours of chemo so I still wake up in the middle of the night and think this is really happening but it is a wonderful place to be in right now." 

Mrs Hardy is being treated by Professor Juan Valle, a leading expert in biliary tract cancer (which includes bile duct cancer) and member of national and international research groups dedicated to improving treatments for patients with the disease.

“We saw breast cancer, lung cancer, bowel cancer all developing new treatments, and we couldn’t get out of the starting box with biliary tract cancer because it was thought it was too rare,” he said.

“But in fact, the problem was, there was no collaboration. So, if you put the whole of the UK together, there are enough patients with biliary tract cancer to run proper trials.

"We can make progress in the field.”

Prof Valle said adding immunotherapy to chemotherapy when patients are first diagnosed has been shown to boost survival.

He said Carol had done well on this combination, but “as happens with most patients, at some point, the cancer started getting worse again.”

This is why he decided to try her on RXC004.

“It’s very early days still. In terms of early drug development, we’re excited by Carol’s story about how well this is doing, but obviously we need to test it in a bigger group of patients.

“At this stage, the trial Carol is on wouldn’t change practice, but it would be the springboard to a much bigger trial.”

The Christie has two groups testing the new drug – Carol and one other patient with biliary tract cancer, and two patients with pancreatic cancer.

Cancer centres across the UK are also recruiting, with the hope 20 patients can be put on the trial.

There is a hope that the drug in the clinical trial could be used for other cancers, possibly including bowel cancer.

As for future goals, Mrs Hardy said just wants to spend as much time as she can with her family.

“I want to see my daughter grow, get married, perhaps have children if she wants to,” she said.

“Those are the things that can upset you. You just want to live as long as you can.”

Want a quick and expert briefing on the biggest news stories? Listen to our latest podcasts to find out What You Need To know